Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Targets |
CYP3A4 (IC50 = 36.63 μM); CYP2C9 (IC50 = 75.76 μM)
|
---|---|
ln Vitro |
Nitric oxide (NO) production, pro-inflammatory cytokines (IL-6) and (TNF-α) and pro-inflammatory protein expression, iNOS, and COX-2 expression are all significantly reduced by curcumenol in response to LPS. Hepatoprotective qualities of curcumenol have also been demonstrated. By preventing the phosphorylation of Akt, curcumenol can reduce the NF-B activity that LPS causes. Its administration significantly reduces the phosphorylation of p38 MAPK caused by LPS, but not JNK or ERK[1]. With an IC50 value of 12.6 1.3 M, curcumenol significantly reduces the activity of CYP3A4. With a Ki of 10.8 μM, kinetic analysis demonstrates curcumenol's competitive inhibition of testosterone 6β-hydroxylation activity (CYP3A4)[2].
|
ln Vivo |
In a sterile 96-well plate with a flat bottom, BV-2 cells are seeded. The following day, the cells are allowed to adhere. The cells are first pretreated with different concentrations of curcumenol for 2 hours, then exposed to LPS (0.4 μg/mL) for 12 to 24 hours.
|
References |
Molecular Formula |
C15H22O2
|
---|---|
Molecular Weight |
234.339
|
Exact Mass |
234.162
|
Elemental Analysis |
C, 76.88; H, 9.46; O, 13.65
|
CAS # |
19431-84-6
|
Related CAS # |
19431-84-6
|
Appearance |
Solid powder
|
SMILES |
C[C@H]1CC[C@@H]2[C@]13CC(=C(C)C)[C@](O3)(C=C2C)O
|
InChi Key |
ISFMXVMWEWLJGJ-NZBPQXDJSA-N
|
InChi Code |
InChI=1S/C15H22O2/c1-9(2)13-8-14-11(4)5-6-12(14)10(3)7-15(13,16)17-14/h7,11-12,16H,5-6,8H2,1-4H3/t11-,12-,14-,15+/m0/s1
|
Chemical Name |
(1S,2S,5S,8R)-2,6-dimethyl-9-propan-2-ylidene-11-oxatricyclo[6.2.1.01,5]undec-6-en-8-ol
|
Synonyms |
Curcumenol
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 46~125 mg/mL (196.3~533.4 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.2673 mL | 21.3365 mL | 42.6730 mL | |
5 mM | 0.8535 mL | 4.2673 mL | 8.5346 mL | |
10 mM | 0.4267 mL | 2.1337 mL | 4.2673 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.